Australia markets open in 5 hours 29 minutes

JW Pharmaceutical Corporation (001067.KS)

KSE - KSE Delayed price. Currency in KRW
Add to watchlist
59,000.00-500.00 (-0.84%)
At close: 03:30PM KST
Currency in KRW

Valuation measures4

Market cap (intra-day) 711.38B
Enterprise value 791.47B
Trailing P/E 39.56
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.96
Price/book (mrq)5.28
Enterprise value/revenue 1.06
Enterprise value/EBITDA 8.80

Trading information

Stock price history

Beta (5Y monthly) 0.61
52-week change 3-3.21%
S&P500 52-week change 322.36%
52-week high 365,196.08
52-week low 30.00
50-day moving average 360,122.00
200-day moving average 361,309.57

Share statistics

Avg vol (3-month) 336
Avg vol (10-day) 322
Shares outstanding 5206.93k
Implied shares outstanding 610.62M
Float 812.27M
% held by insiders 13.59%
% held by institutions 10.00%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4400
Forward annual dividend yield 40.67%
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 40.59
Payout ratio 426.60%
Dividend date 3N/A
Ex-dividend date 427 Dec 2023
Last split factor 21.02:1
Last split date 327 Dec 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 4.94%
Operating margin (ttm)16.07%

Management effectiveness

Return on assets (ttm)9.49%
Return on equity (ttm)15.65%

Income statement

Revenue (ttm)748.53B
Revenue per share (ttm)16,270.54
Quarterly revenue growth (yoy)6.10%
Gross profit (ttm)N/A
EBITDA 119.21B
Net income avi to common (ttm)37.01B
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)91.50%

Balance sheet

Total cash (mrq)94.2B
Total cash per share (mrq)4,036.96
Total debt (mrq)170.28B
Total debt/equity (mrq)64.15%
Current ratio (mrq)1.32
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)87.16B
Levered free cash flow (ttm)23.38B